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PA2.26 antigen was originally identified as a small
mucin-type glycoprotein induced during chemical
carcinogenesis on mouse skin. Cloning and sequen-
cing of the murine and human PA2.26 cDNAs revea-
led that the sequence was identical to other repor-
ted proteins termed T1a (a marker for alveolar type
I epithelial cells) and podoplanin (a glycoprotein
expressed in glomerular podocytes). In this review,
we summarise the current knowledge on the bio-
logy of PA2.26 (T1a /podoplanin). Although the phy-
siological function of this protein is not well esta-
blished as yet, several characteristics make this
molecule unique among mucin-like glycoproteins.
For example, PA2.26 (T1a /podoplanin) appears to
play an important role in morphogenesis during de-
velopment, and it is a marker for the lymphatic en-
dothelium. In cancer, PA2.26 is induced in tumours
derived from squamous epithelia, and is associated
with cell migration and malignant progression.
These findings are discussed in the context of can-
cer-associated membrane mucins in which PA2.26
antigen, together with a newly-discovered small
mucin called dysadherin, form a special group. 
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Antígeno PA2.26 (T1a /podoplanina): 
una glucoproteína transmembrana tipo
mucina de pequeño tamaño asociada con
la migración celular y el cáncer
El antígeno PA2.26 fue identificado originalmente
como una glucoproteína tipo mucina de pequeño
tamaño cuya expresión se induce durante la carci-
nogénesis química de piel de ratón. El clonaje y la
secuenciación de los cADNs murino y humano re-
veló que PA2.26 era idéntica a otras proteínas cono-
cidas, denominadas como T1a (un marcador para
células epiteliales tipo I de los alvéolos) y podopla-
nina (una glucoproteína presente en los podocitos
de los glomérulos). En esta revisión resumimos lo
que se sabe actualmente sobre la biología de PA2.26
(T1a /podoplanina). Aunque la función fisiológica
de esta proteína no se conoce todavía en profundi-
dad, ciertas características de esta molécula la ha-
cen única entre las glucoproteínas tipo mucina. Así,
PA2.26 (T1a /podoplanina) parece desempeñar un
papel importante en la morfogénesis durante el de-
sarrollo embrionario, y es un marcador del endote-
lio linfático. En el cáncer, PA2.26 se induce en tu-
mores derivados de epitelios escamosos, asociada
con la migración celular y la progresión maligna.
Estos hallazgos se discuten en el contexto de las
mucinas transmembrana relacionadas con el cán-
cer, de las cuales el antígeno PA2.26 junto con de-
sadherina, otra mucina de pequeño tamaño descu-
bierta recientemente, forman un grupo especial.
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INTRODUCTION
Mucins are very large glycoproteins (>200 kDa) that
contain 50%-80% carbohydrates by weight, predomi-
nantly O-linked sugars to the abundant Ser and Thr
residues present in their backbones. They are the ma-
jor constituents of viscous mucus in the tracheobron-
chial, gastrointestinal and reproductive tracts, for-
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ming highly disulfide cross-linked gels that serve as
lubricants and protection of the underlying epithelia1.
A second class of mucins, the membrane-associated
mucins, differ greatly in structure and function from
the secreted mucins. The typical membrane-associa-
ted mucins contain a hydrophobic membrane-span-
ning domain and a large extracellular domain consis-
ting of repetitive mucin sequences and many Pro
residues, that results in an extended and rigid struc-
ture that may reach a length of several hundred nano-
meters1,2. Epithelial transmembrane mucins have 
received increasing attention, first because their en-
hanced expression in carcinomas and adhesive mo-
dulating properties2, and second for their involvement
in cellular signaling3. Although about a dozen of
membrane mucin genes have been cloned from diffe-
rent species, the best characterized are MUC1 (episia-
lin) and MUC4 (sialomucin).
MUC1 is present in simple secretory epithelial tis-
sues, and the elevated levels of expression found in
carcinomas and metastatic lesions suggest that it has
a role in tumor progression and metastasis1. It is
thought to be an anti-adhesive molecule due to its lar-
ge, extended, extracellular domain that reduces cell-
cell and cell-substratum adhesion by steric hyndran-
ce4,5, but MUC1 on pancreas and colon carcinoma
cells has adhesive features because it presents car-
bohydrate structures that might be ligands for selec-
tins on endothelial cells, enabling metastatic dissemi-
nation of cancer cells6,7. On the other hand, several
observations suggest that MUC1 might play a role in
cellular signaling since it bind members of the ErbB
family of tyrosine kinase receptors3. MUC1 also inte-
racts with b -catenin8, a component of cell-cell adhe-
rens junctions and a regulator of transcription that
acts as an oncoprotein in colorectal cancer9. A more
clear indication of a cell signaling function for mu-
cins has come from studies with MUC4, a heterodi-
meric glycoprotein complex with anti-adhesive pro-
perties originally identified in highly metastatic rat
mammary adenocarcinoma cells10. The transmem-
brane subunit of MUC4 (ASPG-2) is the only ligand to
date characterized for ErbB2. MUC4 binding to ErbB2
induces Tyr phosphorylation of the receptor and en-
hances expression of the cyclin-dependent kinase 
inhibitor p27kip, an effect that is reversed by neuregu-
lin11, a ligand for ErbB3 for which ErbB2 is conside-
red a co-receptor.
Other membrane mucins present in blood endothelial
cells and leukocytes function as ligands for the selec-
tin family of carbohidrate-binding proteins. These
mucins are involved in cell-cell interactions and me-
diate leukocyte migration from the blood stream into
tissue, thrombosis and inflammation12,13. Prototypic
mucins from this group are CD34 (Mr 90 kDa), a li-
gand for L-selectin which is expressed in endothelial
cells and in pluripotent stem cell of the bone marrow,
and CD43 (sialophorin, leukosialin, Mr 100-150 kDa),
expressed in leukocytes and platelets, which is defec-
tive in patients with the X-linked Wiskott-Aldrich syn-
drome, a profound immunodefficiency in T-cell func-
tion. 
In this article, we will review the properties of PA2.26
antigen, a small membrane-associated mucin origi-
nally identified as a cell-surface glycoprotein induced
in basal epidermal keratinocytes and dermal fibro-
blast-like cells during mouse skin carcinogenesis and
wound healing14,15.
PA2.26 ANTIGEN: A NOVEL CELL-SURFACE
MUCIN-TYPE GLYCOPROTEIN
Structure of PA2.26 antigen
PA2.26 protein was identified by a monoclonal anti-
body produced against mouse epidermal keratinocy-
tes transformed by the chemical carcinogen dimethyl-
benzanthracene (DMBA)14. Cloning and sequencing
of the murine PA2.26 cDNA15 revealed a backbone of
172 amino acids containing an N-terminal signal pep-
tide sequence and a highly hydrophobic membrane
spanning domain. The extracellular domain contai-
ned only a putative N-glycosylation site while poten-
tial O-glycosylation Ser and Thr residues were very
abundant. In fact, the biochemical characterization of
immunopurified PA2.26 revealed that it is a highly
glycosylated mucin-type protein containing sialic acid
linked a (2-3) to galactose b (1-3)N-acetylgalactosami-
ne15 (fig. 1A, B). The extremely short cytoplasmic do-
main composed of only 9 amino acids has not ob-
vious functional motifs except a Ser (Ser 167) which
is a potential phosphorylation site for cAMP-depen-
dent protein kinase (PKA) and protein kinase C (PKC)
and a cluster of basic aminoacids reported to be a
binding site for proteins of the ezrin, radixin, moesin
(ERM) family16. ERM proteins play structural and re-
gulatory roles in the formation of cell-surface exten-
sions by linking transmembrane proteins to the actin
cytoskeleton17, and the interaction of PA2.26 with pro-
teins of this family could be a key event for the biolo-
gical action exerted by PA2.26 in the cells (see below).
We have recently cloned the full human PA2.26 cDNA
(Martín-Villar et al, submitted) and found that its ami-
no acid sequence is highly conserved respect to the
mouse protein, particularly in the transmembrane
and cytoplasmic domains. Interestingly, the human
endodomain conserves the putative ERM binding site
as well as the potential phosphorylation site for PKA
and PKC, suggesting that these two motifs are functio-
nally important (fig. 1A). The human and mouse
PA2.26 genes are located in chromosomes 1 and 4,
respectively. They encode polypeptides that migrate at
21 kDa (human) and 27 kDa (mouse) in SDS-pol-
yacrylamide gels, while the mature glycosylated
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forms raise sizes of about 40 and 45 kDa, respectively. 
PA2.26 antigen is, therefore, the smallest transmem-
brane mucin known to date. In contrast to large
MUC1 and MUC4 mucins whose ectodomains may
extend at least 200-500 nm above the cell membrane2,
the length of the PA2.26 ectodomain is about 30 nm,
in the range of cell adhesion receptors as integrins
and cadherins (fig. 1C). Recently, a new membrane
glycoprotein of small size, dysadherin, has been clo-
ned from human cells18. Dysadherin is a cancer-asso-
ciated mucin of 178 amino acids whose sequence is
unrelated to PA2.26 but share with PA2.26 structural
and functional similarities (see below).
PA2.26-related proteins: many collars for the same
cat?
Two cDNAs encoding proteins with amino acid se-
quences almost identical to that of PA2.26 were first
described in the mouse: OTS-8 as a phorbol ester-in-
duced gene in cultured osteoblast cells19; and gp38
encoding a marker of type I epithelial cells in the thy-
mus and of stromal cells in T-dependent cell areas of
peripheral lymphoid tissues20. Other PA2.26-related
proteins have been described in different species
(summarized in table 1). Thus, several glycoproteins
which share high identity sequences were identified
in the rat: E11 as a marker for cells of the osteoblastic
lineage21, T1a and RTI40 expressed by alveolar type I
cells in the lung22,23, and podoplanin as a marker of
glomerular epithelial cells (podocytes)24. In addition,
gp40, a canine homologous of PA2.26, has been repor-
ted to act as a main receptor for the influenza C virus
in Madin-Darby canine kidney (MDCK) cells25. The
human homologues for several of these proteins have
also been described: gp36 as the corresponding dog
gp4026, and T1a -1 and T1a -2 as the human isoforms
of rat T1 a 27.
The present evidence suggests that all these proteins
are encoded by the same gene. Thus, the cDNA se-
quences reported for human gp3626, T1a -227 and po-
doplanin (GenBank accession number AF390106) are
identical to that of human PA2.26 (GenBank accession
number AY194238; Martín-Villar et al, submitted),
while the nucleotide sequence reported for the anot-
her human isoform of rat T1 a , T1 a -127 (GenBank ac-
cession number AF030427) seems to be an experi-
mental artifact as it does not correspond to a cDNA
but to a sequence comprising exon 5 and part of the
flanking introns of the PA2.26 gene. Therefore,
PA2.26, T1a and podoplanin are identical proteins.
Nevertheless, although likely all of the above mentio-
ned PA2.26-related proteins (table 1) are encoded by a
single, highly conserved gene, some heterogeneity of
protein products might exist that could account for
discrepancies in the pattern of tissue distribution re-
ported for some of these proteins. This heterogeneity
could be generated either by post-translational modi-
fications (allowing to differences in the recognition by
antibodies) or alternative splicing. In regard with the
latter, no mechanistic explanation has been reported
for the expression of two distinct PA2.26/podoplanin
transcripts of 2.7 and 0.9-kb in human tissues28 (Mar-
tín-Villar et al, submitted). 
EXPRESSION STUDIES 
PA2.26 (T1a /podoplanin) is developmentally
regulated and expressed in a wide variety of cell
types in adult tissues 
PA2.26 antigen exhibits a broad cellular distribution
in adult mouse normal tissues. It is expressed in all
types of mesothelia as well as in epithelial cells of al-
veoli, ependyma, choroid plexuses and glomeruli,
concentrated on the apical side of the cells and asso-
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Fig. 1. Structure of PA2.26 anti-
gen. A) Schematic representa-
tion of the PA2.26 backbone sho-
wing the highly O-glycosylated
ectodomain as well as the positi-
vely charged location for binding
of ERM proteins and potentially
phosphorylated Ser in the endo-
domain. B) O-glycan chains lin-
ked to Ser or Thr in the PA2.26
ectodomain. NANA: N-acetylneu-
raminic acid (sialic acid); Gal:
galactose; GalNAc: N-acetylga-
lactosamine. C) Comparison of
the lengths of ectodomains
among several transmembrane
glycoproteins (in a mucin-like
domain 20-amino acids residues
are approximately 5-nm long).
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ciated with microvilli15. This pattern of expression
coincides with that found for T1 a and podoplanin24,29.
In human tissues, PA2.26 antigen has also been found
to be present in osteocytes, regenerating skeletal
muscle cells and fibroblast-like cells with a dendritic
morphology (Martín-Villar et al, submitted). But the
most remarkable finding raised in these studies is
that PA2.26/podoplanin is specifically expressed in
the lymphatic endothelium, but not in endothelia of
blood vessels in both rodent and human tissues15,30
(Martín-Villar et al, submitted).
Several reports have described that expression of T1 a
is developmentally regulated. During mouse embryo-
nic development it is detected in the foregut endo-
derm at day E8.5-9.0. Its expression pattern changes
during lung morphogenesis from wide-spread in the
embryonic lung epithelium to restricted expression to
type I cells of the distal epithelium22,29,31. The gene is
also expressed in the developing nervous system.
High levels of expression are found in the early neu-
ral tube but, by midgestation the gene is down-regu-
lated being detected only in the choroid plexus in
adult brain15,21,29.
In addition, PA2.26/T1 a /podoplanin is expressed in
lymphatic progenitor cells at around E11.032. These
endothelial cells are located on one side of the ante-
rior cardinal vein and express Prox-1, a homeobox
transcription factor33,34. Prox-1 appears to be a master
control gene that determines lymphatic endothelial
cell fate by repressing expression of blood vascular
endothelial cell-specific genes and inducing lympha-
tic endothelial gene transcription35-37. PA2.26/T1a /po-
doplanin is one of the primary Prox-1-induced ge-
nes37. In contrast to Prox-1-null mice, which fail to
develop any lymphatic vasculature36, PA2.26/T1a /po-
doplanin knock-out mice can develop a peripheral
lymphatic vascular system, but exhibit pronounced
defects in lymphatic vascular organization and func-
tion32 (see below).
The importance of being a specific marker for the
lymphatic endothelium 
The lymphatic vascular system plays an important
physiological role in the control of tissue fluid home-
ostasis and in the immune response. Lymphatic capi-
llaries drain the fluid and proteins exudated into the
tissues and direct antigen-presenting cells to the
lymph nodes. Dysfunction or abnormal development
of lymphatic vessels results in lymphedema, which is
characterized by fluid accumulation (edema), impai-
red immunity and fibrosis38. The lymphatic vascular
system is also involved in the metastatic spread of
malignant tumors. Clinical and pathological observa-
tions suggest that transport of tumor cells via lymp-
hatics is the most common pathway of initial dissemi-
nation to the regional lymph nodes for many
carcinomas38-40. In fact, the detection of lymph node
metastases in cancer patients is significant for both
tumor staging and the design of treatment protocols.
However, despite these well established principles
questions concerning to the mechanisms of tumor
spread via lymphatics still remain unanswered; i. e.,
it is not known whether tumor cells disseminate th-
rough preexisting vessels or whether they require
lymphatic capillaries formed de novo by lymphangio-
genesis40,41. In the studies on cancer, the lymphatic
vascular system has been traditionally overshadowed
by the greater emphasis placed on the blood vascular
system (angiogenesis). This has been due, in part, by
the difficulties in recognizing lymphatic vessels in tis-
sues by only morphological criteria because of the
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TABLE 1. Summary of PA2.26-related proteins
Species Name Identified as References
OTS-8 Phorbol ester-inducible gene in cultured osteoblasts 19
gp38 Marker of stromal cells in T-cell-dependent areas of peripheral lymphoid tissues 20
Mouse Podoplanin Protein that controls the shape of podocytes and is down-regulated 
(gp38P) in experimental nephrosis 53
T1a Marker of alveolar type I epithelial cells of the lung 22
RT140 23
Rat E11 Marker for the late steps in the differentiation pathway of the osteoblastic lineage 21
Podoplanin Protein that controls the shape of podocytes and is down-regulated in 
experimental nephrosis 24
OTS-8 Antigen expressed on rat tumor vascular endothelial cells 54
Dog gp40 Main receptor for influenza C virus 25
T1a Marker of alveolar type I epithelial cells of the lung 27
Human gp36 Sialoglycoprotein expressed at the apical plasma membrane of the vascular
endothelium and alveolar epithelium 26
Podoplanin Lymphatic endothelial marker 30
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absence of lymphatic specific markers42. Although a
number of lymphatic specific markers have been re-
cently reported, such as the transcription factor Prox-1,
the vascular endothelial growth factor receptor
VEGFR-3/flt-4 and the hyaluronan receptor LYVE-1,
among others, many of them are also expressed in
blood vessels in certain physiological and pathologi-
cal situations or are only present in lymphatic vessels
of certain tissues (see reference 40 for a review). In
contrast, PA2.26/podoplanin appears to be a reliable
marker for lymphatic capillaries (it is not expressed
in the large lymphatic collectors ducts) in all normal
and pathological situations studied to date. Conse-
quently, specific antibodies recognizing PA2.26/podo-
planin are now being widely used to study the lymp-
hatic microvasculature in human cancer43,44.
PA2.26 ANTIGEN AND CANCER
PA2.26 is induced in squamous cell carcinomas
PA2.26 antigen was first identified in the experimen-
tal model of mouse skin carcinogenesis14. PA2.26 is
absent from the normal epidermis as well as from
cultured nontumorigenic keratinocytes but it is pre-
sent in skin carcinoma cell lines. In vivo, it is induced
at a high frequency in basal-like cells of mouse skin
papillomas and carcinomas generated by treatment
with DMBA and TPA. In addition, the antigen is
abundantly synthesized by stromal cells of the tumors
and cultured fibroblasts14. Studies on human cancer
indicate that PA2.26 is not expressed in breast, colo-
rectal, gastric and lung adenocarcinomas and mela-
nomas. Nevertheless, PA2.26 is induced in a subset of
early oral squamous cell carcinomas (Martín-Villar et
al, submitted). Taken together, these observations
suggest that PA2.26 could be a marker for tumors de-
rived from squamous stratified epithelia. 
This is in contrast to dysadherin, another small can-
cer-associated membrane mucin which is expressed
in a wide variety of carcinomas including those deri-
ved from the pancreas, breast, colon, lung, stomach
and bladder18,45,46. Dysadherin is also expressed in
normal lymphocytes, blood vascular endothelial cells
and, interestingly, in basal cells of normal stratified
squamous epithelia18. Although PA2.26 is absent from
the normal stratified epithelia, it is induced in basal
epidermal keratinocytes during wound healing and
after treatment of the skin with TPA14. PA2.26 is also
expressed in the hyperplastic epithelium adjacent to
oral squamous carcinomas (Martín-Villar et al, sub-
mitted) always restricted to the basal proliferative la-
yer, and no expression has been found in differentia-
ting suprabasal keratinocytes. These results indicate
that PA2.26 might be involved in reactive processes
during tissue remodeling and carcinogenesis. Wound
healing and tumor development are dynamic proces-
ses that implicate the interaction of several tissue ty-
pes. These interactions are potentiated by reciprocal
signaling between the epithelium and stromal fibro-
blasts and involve paracrine diffusible growth factors
that stimulates infiltration of macrophages, promotes
angiogenesis, reduces epithelial adhesiveness and in-
creases epithelial cell proliferation and migration47.
PA2.26 expression during wound healing and carci-
nogenesis could be induced by growth factors or cyto-
kines that stimulate proliferation and/or locomotion
of basal keratinocytes. 
PA2.26 promotes cell migration and metastasis
The first evidence for a relationship between PA2.26
antigen and cell migration came from confocal im-
munofluorescence and electron microscopy studies
aimed to determine the subcellular localization of the
antigen in carcinoma and fibroblast cell lines. PA2.26
was concentrated in actin-rich microvilli and plasma
membrane extensions, such as filopodia, lamellipodia
and ruffles, where it colocalized with members of 
the ERM protein family and actin filaments15 (fig. 2). 
ERM proteins appear to regulate many fundamental
cellular processes involving the plasma membrane
and underlying actin cytoskeleton, such as cell shape,
cell migration, membrane trafficking and membrane
transport. Furthermore, there is evidence supporting
a role for ERM proteins in signal transduction. ERM
proteins bind the Rho GDP dissociation inhibitor
(RhoGDI), a sequestering and negative regulator of
Rho GTPase, allowing activation of the Rho
pathway48. ERM proteins have been reported to an-
chorage several cell adhesion molecules as CD44,
ICAM-2 and CD43 directly to actin filaments. For ot-
her proteins, such as the PDGF receptor and the cys-
tic fibrosis transmembrane conductance regulator
CFTR, linking to F-actin is indirect and requires bin-
ding of ERM to scaffolding proteins17. Immunopreci-
pitation of PA2.26 from cell lysates coprecipitated ez-
rin and moesin, but not radixin15. Furthermore,
pull-down experiments with the intact and mutant
PA2.26 endodomains coupled to Sepharose suggest
that PA2.26 binds ezrin directly through the juxta-
membrane cluster of positively charged amino acids
present in its endodomain (Scholl and Quintanilla,
unpublished results). The fact that radixin does not
appear to bind PA2.26 is in agreement with the relati-
ve distribution found for ERM proteins and PA2.26 in
vivo. While the tissue distribution of PA2.26 coincides
with that of ezrin or moesin in polarized cells of me-
sothelia, choroid plexuses, alveoli and glomeruli15,49,
concentrated in microvilli or cell-surface protrusions,
radixin is primarily expressed in cells that do not ex-
press PA2.26, such as hepatocytes and bile canaliculi50. 
Transfection of PA2.26 cDNA into immortalized pre-
malignant keratinocytes promoted plasma membrane
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extensions and cell migration15. PA2.26 induced a re-
distribution of ezrin from short microvilli to longer fi-
lopodia, lamellipodia and ruffles allowing to a reorga-
nization of the actin cytoskeleton in which cortical
actin bundles and stress fibers were lost. Importantly,
E-cadherin was anomalously localized out of cell-cell
contacts and proteolitically degraded leading to desta-
bilization of cell-cell junctions and enhanced invasi-
veness and metastasis51. Upon injection in nude mice,
PA2.26 transfectants produced highly undifferentiated
carcinomas that metastasized into regional lymph no-
des, while parental cells and control transfectants ga-
ve rise as much to small cysts of benign appearance51. 
The induction of elongated cell extensions and cytos-
keletal reorganization, together with the enhanced
migration of stably PA2.26-transfected keratinocytes,
are in agreement with the effects on the motility of
endothelial cells observed after transfection of T1a /po-
doplanin32. These results suggest an important role
for PA2.26 on the induction and stabilization of cellular
protrusions at the leading edge of migrating cells. In
cancer cells, the effects of PA2.26 on the plasma mem-
brane and cytoskeleton could suppress E-cadherin
function allowing to enhanced invasiveness and me-
tastasis. Similar effects on cell-cell adhesion and 
E-cadherin expression have been observed for dysad-
herin. Dysadherin tends to be expressed in tumor re-
gions where cell-cell contacts are loose, and transfec-
tion of dysadherin into liver cancer cells resulted in
down-regulation of E-cadherin protein expression
and enhanced metastasis18. Dysadherin has been
found to interact with actin filaments18, although its
association with ERM proteins remains as an open
question. 
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Fig. 2. PA2.26 is concentrated
at plasma membrane projec-
tions. A and B) Confocal im-
munofluorescence colocaliza-
tion of PA2.26 with actin
filaments (F-actin) at cell-sur-
face extensions in carcinoma
cells. C) Immunoelectron mi-
croscopic localization of
PA2.26 at membrane microvilli
in carcinoma cells. 
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Overally, small cancer-associated membrane mucins
appear to play a key role in malignant progression.
They can inactivate E-cadherin function without af-
fecting its expression at the mRNA level by a novel
mechanism that involves a reorganization of the actin
cytoskeleton. We have postulated that this mechanism
implicates the interaction of the cytoplasmic domain
of PA2.26 with ezrin51. However, a contribution of the
glycoprotein ectodomain can not be ruled out at pre-
sent.
TOWARDS A BIOLOGICAL FUNCTION 
FOR PA2.26 (T1a /PODOPLANIN) 
The presence of PA2.26 in relatively fixed cells in nor-
mal tissues suggest another function besides its pos-
tulated role in cell migration and malignant progres-
sion. In this regard, the generation of T1a null mice
containing a targeted mutation in the T1a gene locus
has revealed important insights about the function of
PA2.26/T1 a /podoplanin in normal cells and tissues.
While mice with heterozygous disruption of the T1a
gene were healthy and fertile, T1a null mice died im-
mediately after birth, due to respiratory failure cau-
sed by impaired formation of alveolar airspace and
reduced numbers of differentiated type I alveolar epit-
helial cells in the lung31. Although the function of T1a
in the alveolar epithelium is unknown, the lung phe-
notype of T1 a null mice appears to be related to a ge-
neral dysregulation of proliferation in the distal lung
at the expense of correct type I cell differentiation,
possibly by disruption of epithelial-mesenchymal sig-
naling31. The T1a null mice also showed defects in
the lymphatic, but not blood vessel pattern formation.
These defects were associated with congenital lymp-
hedema, dilation of lymphatic vessels and diminished
lymphatic transport and have been attributed to im-
paired cell to substratum adhesion and migration32.
These results suggest an important role for this glyco-
protein in the development of the lung and lymphatic
vascular system, but additional studies are required
to unravel the precise function of PA2.26/T1 a /podo-
planin in the alveolar epithelium and lymphatic en-
dothelial cells.
The localization of PA2.26/T1 a /podoplanin at the api-
cal cell surface of mesothelial, epithelial and endothe-
lial cells, at membrane regions exposed to an internal
or external fluid compartment, together with its nega-
tively charged structure typical of mucins are compa-
tible with a protective function from environmental
agents and proteases1,2. On the other hand, a role for
this glycoprotein in fluid transport has also been pro-
posed, although studies aimed to demonstrate this hy-
pothesis have failed27. 
PA2.26 could also act as a ligand for lectins, as do se-
lectin-binding mucins present in blood endothelial
cells and leukocytes12. In this regard, it is of interest
to emphasize that carbohydrate modifications in the
ectodomain of PA2.26 (sialic acid linked a (2-3) to ga-
lactose b (1-3)N-acetylgalactosamine) (fig. 1) is an op-
timal location for recognition by lectins that bind sia-
lic acid, also denominated Siglecs (Sialic acid-binding
immunoglobulin superfamily lectins)52. However,
nothing is known about the possible interactions of
PA2.26 with other extracellular proteins or matrix
components.
In summary, PA2.26 antigen appears to fullfil several
functions during late development, tissue repair and
carcinogenesis. While its involvement in cell motility
has been clearly demonstrated in keratinocytes and
endothelial cells15,32,51, further work is necessary to
analyze its possible role in other cellular processes
such as cell adhesion and signal transduction. To this
end, the knowledge of interactions of PA2.26 with ot-
her membrane proteins or extracellular components
will be of paramount interest in the future.
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